An Ottawa-based bioscience company working to develop pharmaceuticals derived from cannabis says it’s closed a multimillion-dollar funding round to help advance its clinical testing of a drug to treat chronic pain.
Tetra Bio-Pharma, which is developing cannabinoid-based treatments for chronic pain related to cancer, says it’s closed a public offering of 35,191,000 units at a price of 26 cents each, for aggregate gross proceeds of $9,149,660.
The funds will be used to advance the company’s work on QIXLEEF, a therapy to treat uncontrolled pain in advanced cancer patients that’s in the late-phase drug development stage.
(Sponsored)
Borden Ladner Gervais LLP and partners lead with generosity
Borden Ladner Gervais LLP (BLG) are no strangers to supporting charities in the nation’s capital. From the Boys & Girls Club of Ottawa to Crohn’s and Colitis Canada to the
SnowBall 2026: A premier networking event with purpose returns to 50 Sussex Dr.
As winter settles in across the capital, one of Ottawa’s most high-profile charitable and business networking events is set to return to its roots: On Wed., March 4, 2026, The
The offering was led by Raymond James Ltd. and Canaccord Genuity Corp. and included Echelon Wealth Partners Inc.
Tetra Bio-Pharma’s share price rose Friday after the funding was announced, but slipped slightly Monday to 23 cents in mid-afternoon trading on the TSX Venture Exchange.
